Biogen (NASDAQ:BIIB) Given New $200.00 Price Target at Sanford C. Bernstein

Posted by Geri Gentry on May 1st, 2026

Biogen (NASDAQ:BIIB – Free Report) had its price target cut by Sanford C. Bernstein from $201.00 to $200.00 in a research report released on Thursday,MarketScreener reports.

BIIB has been the topic of a number of other research reports. Stifel Nicolaus lifted their price objective on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Wedbush raised their target price on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research note on Thursday. Wolfe Research set a $231.00 price target on shares of Biogen in a report on Monday, February 9th. Wells Fargo & Company upped their price target on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Finally, HC Wainwright increased their price objective on Biogen from $228.00 to $237.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Fourteen research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $213.85.

Read Our Latest Report on Biogen

Biogen Stock Up 0.1%

Shares of BIIB traded up $0.12 during trading hours on Thursday, hitting $189.40. The company had a trading volume of 98,279 shares, compared to its average volume of 1,317,249. The company has a current ratio of 3.06, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $27.80 billion, a PE ratio of 20.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.16. Biogen has a one year low of $115.25 and a one year high of $202.41. The company’s fifty day moving average price is $184.52 and its two-hundred day moving average price is $176.06.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the company earned $3.02 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts forecast that Biogen will post 14.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Institutional Investors Weigh In On Biogen

Large investors have recently bought and sold shares of the company. Simplicity Wealth LLC raised its position in Biogen by 10.1% during the 1st quarter. Simplicity Wealth LLC now owns 2,149 shares of the biotechnology company’s stock worth $394,000 after buying an additional 197 shares during the last quarter. Candriam S.C.A. boosted its holdings in shares of Biogen by 15.5% in the 1st quarter. Candriam S.C.A. now owns 381,768 shares of the biotechnology company’s stock valued at $69,990,000 after acquiring an additional 51,296 shares during the last quarter. Kestra Advisory Services LLC increased its stake in shares of Biogen by 28.9% in the first quarter. Kestra Advisory Services LLC now owns 5,810 shares of the biotechnology company’s stock worth $1,065,000 after acquiring an additional 1,301 shares during the period. Resona Asset Management Co. Ltd. increased its stake in shares of Biogen by 2.4% in the first quarter. Resona Asset Management Co. Ltd. now owns 46,261 shares of the biotechnology company’s stock worth $8,518,000 after acquiring an additional 1,075 shares during the period. Finally, Munich Reinsurance Co Stock Corp in Munich purchased a new position in shares of Biogen during the first quarter worth $4,389,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Biogen

(Get Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.